Skip to main content
Caplight Logo









Mirugen

Mirugen

Private
MelbourneHealthcare & Life Scienceshttps://www.mirugen.com/

Last Round

Seed

Aug 14, 2025

Total Funding Raised

$4.55M

Company Overview

Mirugen is a biotechnology company developing gene therapy to treat blindness by reprogramming cells to unlock innate cellular repair mechanisms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Application

Keywords

gene therapycellular reprogrammingvision restorationphotoreceptor regenerationretinitis pigmentosain-vivo reprogrammingregenerative medicinepreclinical biotechAAV gene therapycomputational biologyretinal regenerationage-related macular degenerationbioinformaticsdrug discovery platformStargardt's diseasetranscription factors

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mirugen Comparables

Compare Mirugen with similar companies based on industry and business-model similarity.

Mirugen comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ray Therapeutics
78%
Life Biosciences
77%
SparingVision
76%

Mirugen Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedAug 14, 2025
GrantDec 23, 2024

Key People

Founding team and executive leadership

Raymond Wong

Founder Chief Scientific Officer

Founding Team

Mirugen Investors

Notable investors and investment history

Mirugen investors
InvestorRounds
CUREatorGrant
ANDHealthGrant
Brandon CapitalSeed
Tin Alley VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 14, 2025

    $3M round led by Brandon Capital, genesispsf, and Tin Alley Ventures.

  • Dec 23, 2024

    $1.27M grant round led by CUREator.

Mirugen Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Mirugen Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Mirugen's valuation, stock price, and market status.

Firmographic Details

HeadquartersMelbourne
Employee Range3
Year Founded2022
Last FundingAug 14, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?